Studying blood samples to predict myeloma progression in screened people
Collects blood samples from people screened for early myeloma and from the general population.
Plain-language title generated from the registry record
Registry title: Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
Key facts
- Where
- Beersheba, Haifa, Petah Tikva, and Tel Aviv, IsraelSee the 4 sites
Where in Israel
- SorokaBeersheba, IsraelTaking people
- Rambam Healthcare CampusHaifa, IsraelTaking people
- Rabin Medical CenterPetah Tikva, IsraelTaking people
- TASMCTel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Trial code
- NCT05837884
- Record updated
- 11 August 2026
- Original description
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.Read full original descriptionShow less
Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.
Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.
Inclusion: Must meet criteria of the high-risk population as described with one of the below criteria; ≥ 30 years AND; first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer; OR; Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '; Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
Exclusion: • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy; Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia; Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.